



Firalis SAS is a biotech company with unique expertise in clinical biomarker (BM) development, located in the Alsacian region of Biovalley. Firalis has academic and global pharmaceutical talents in BM R&D and develops proprietary vascular and kidney injury BMs for clinical applications and established a unique EU network of clinical centers of excellence to conduct clinical BM qualification studies.

Discovery, and in particular, “clinical qualification” of candidate BMs is its domain of excellence. Firalis is a unique company that has proprietary BMs for the early prediction of drug induced vascular injury. Firalis has leading expertise in integrative data analysis and develops BM-based diagnostic kits to predict cardio-vascular adverse events.

www.firalis.com